Art. -Nr.: HY-10194

Copy Link Print Information

Sepantronium bromide

(Synonyms: YM-155)

23 Cited Publications

Kundenbewertung

Based on 23 publication(s) in Google Scholar

Sepantronium bromide (YM-155) is a survivin inhibitor with an IC₅₀ of 0.54 nM.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.36%
CAS. Nr.: 781661-94-7
Formel: C₂₀H₁₉BrN₄O₃
Molecular Weight:443.29

Speicherung:

4°C, sealed storage, away from moisture

* In solvent : -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture)

Sepantronium bromide Chemical Structure

CAS. Nr.: 781661-94-7

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (23)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Protokoll
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Sepantronium bromide (YM-155) is a survivin inhibitor with an IC₅₀ of 0.54 nM^[1].

IC₅₀ & Target

IC50: 0.54 nM (Survivin)^[1]

Cellular Effect

Cell Line	Type	Value	Description	References
143B	IC₅₀	0.32 μM Compound: YM155	Antiproliferative activity against human 143B cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay Antiproliferative activity against human 143B cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay	[PMID: 38079530]
5637	IC₅₀	0.11 μM Compound: YM155	Antiproliferative activity against human 5637 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay Antiproliferative activity against human 5637 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay	[PMID: 38079530]
A-375	IC₅₀	0.006 μM Compound: 1; YM155	Anticancer activity against human A375 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Anticancer activity against human A375 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 38092421]
A549	IC₅₀	0.0134 μM Compound: YM155	Growth inhibition of human A549 cells Growth inhibition of human A549 cells	[PMID: 28814374]
A549	IC₅₀	0.01 μM Compound: YM155	Antiproliferative activity against human A549 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay	[PMID: 38079530]
ASPC1	IC₅₀	0.51 μM Compound: YM155	Antiproliferative activity against human ASPC1 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay Antiproliferative activity against human ASPC1 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay	[PMID: 38079530]
BXPC-3	IC₅₀	0.09 μM Compound: YM155	Antiproliferative activity against human BXPC-3 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay Antiproliferative activity against human BXPC-3 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay	[PMID: 38079530]
CWR22R	IC₅₀	0.011 μM Compound: 1; YM155	Cytotoxicity against human 22Rv1 cells assessed as cell growth inhibition Cytotoxicity against human 22Rv1 cells assessed as cell growth inhibition	[PMID: 38092421]
DU-145	EC₅₀	13.8 nM Compound: YM155	Cytotoxicity against human DU145 cells by MTT assay Cytotoxicity against human DU145 cells by MTT assay	[PMID: 28774426]
DU-145	IC₅₀	0.004 μM Compound: 1; YM155	Cytotoxicity against human DU-145 cells assessed as reduction in cell viability by SRB assay Cytotoxicity against human DU-145 cells assessed as reduction in cell viability by SRB assay	[PMID: 38092421]
HeLa	IC₅₀	1.8 μM Compound: YM155	Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay	[PMID: 38079530]
HepG2	IC₅₀	3.72 μM Compound: YM155	Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay	[PMID: 38079530]
HUVEC	IC₅₀	0.5 nM Compound: YM155	Antiangiogenic activity in HUVEC Antiangiogenic activity in HUVEC	[PMID: 28814374]
HUVEC	IC₅₀	0.5 nmol Compound: YM155	Antiangiogenic activity in HUVEC Antiangiogenic activity in HUVEC	[PMID: 28814374]
HUVEC	IC₅₀	0.92 μM Compound: YM155	Antiproliferative activity against human HUVEC cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay Antiproliferative activity against human HUVEC cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay	[PMID: 38079530]
MCF7	IC₅₀	0.01 μM Compound: YM155	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay	[PMID: 38079530]
MDA-MB-435	IC₅₀	>1 μM Compound: YM-155	Antiproliferative activity against human MDA-MB-435/LCC6MDR cells assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Antiproliferative activity against human MDA-MB-435/LCC6MDR cells assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 34371464]
MDA-MB-435	IC₅₀	2.4 μM Compound: YM-155	Antiproliferative activity against human MDA-MB-435 cells assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Antiproliferative activity against human MDA-MB-435 cells assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 34371464]
MRC5	IC₅₀	1.94 μM Compound: YM155	Antiproliferative activity against human MRC5 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay Antiproliferative activity against human MRC5 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay	[PMID: 38079530]
NCI-H1299	IC₅₀	0.12 μM Compound: YM155	Antiproliferative activity against human NCI-H1299 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay Antiproliferative activity against human NCI-H1299 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay	[PMID: 38079530]
NCI-H460	IC₅₀	0.1 μM Compound: YM155	Antiproliferative activity against human NCI-H460 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay Antiproliferative activity against human NCI-H460 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay	[PMID: 38079530]
NIH3T3	IC₅₀	13.6 μM Compound: YM155	Antiproliferative activity against mouse NIH3T3 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay Antiproliferative activity against mouse NIH3T3 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay	[PMID: 38079530]
PANC-1	IC₅₀	0.01 μM Compound: YM155	Antiproliferative activity against human PANC-1 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay Antiproliferative activity against human PANC-1 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay	[PMID: 38079530]
PC-3	EC₅₀	92 nM Compound: YM155	Cytotoxicity against human PC3 cells by MTT assay Cytotoxicity against human PC3 cells by MTT assay	[PMID: 28774426]
SK-MEL-5	IC₅₀	0.004 μM Compound: 1; YM155	Antiproliferative activity against human SK-MEL-5 cells assessed as reduction in cell viability Antiproliferative activity against human SK-MEL-5 cells assessed as reduction in cell viability	[PMID: 38092421]
TE-1	IC₅₀	0.008 μM Compound: YM155	Antiproliferative activity against human TE-1 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay Antiproliferative activity against human TE-1 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay	[PMID: 38079530]
Vero C1008	CC₅₀	400 μM Compound: 27; YM155	Cytotoxicity against African green monkey Vero E6 cells assessed as cell viability treated for 24 hrs by CCK8 assay Cytotoxicity against African green monkey Vero E6 cells assessed as cell viability treated for 24 hrs by CCK8 assay	[PMID: 35620927]

In Vitro

Sepantronium bromide (YM155; 30 μM) is not sensitive to survivn gene promoter-driven luciferase reporter activity. Sepantronium bromide shows significant supression on endogenous survivin expression in PC-3 and PPC-1 human HRPC cells with deficient p53 via transcriptional inhibition of the survivin gene promoter. Sepantronium bromide (100 nM) does not affect protein expression of c-IAP2, XIAP, Bcl-2, Bcl-xL, Bad, α-actin, and β-tubulin. Sepantronium bromide potently inhibits human cancer cell lines (mutated or truncated p53) such as PC-3, PPC-1, DU145, TSU-Pr1, 22Rv1, SK-MEL-5 and A375 with IC₅₀s ranging from 2.3 to 11 nM, respectively^[1].
Sepantronium bromide (YM155) resultin in an increase in sensitivity of NSCLC cells to γ-radiation. Sepantronium bromide combined with γ-radiation increases both the number of apoptotic cells and the activity of caspase-3. In addition, Sepantronium bromide delays the repair of radiation-induced double-strand breaks in nuclear DNA^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Sepantronium bromide (YM155; 3 and 10 mg/kg) inhibits the tumor growth in PC-3 xenografts, without obvious body weight loss and blood cell count decrease. Sepantronium bromide is highly distributed to tumor tissue in vivo. Sepantronium bromide shows 80% TGI at a dose of 5 mg/kg in PC-3 orthotopic xenografts^[1].
Sepantronium bromide (YM155) in combination with γ-radiation shows potent antitumor activity against H460 or Calu6 xenografts in nude mice^[2].
In this orthotopic renal and metastatic lung tumors models, Sepantronium bromide (YM-155) and IL-2 additively decreases tumor weight, lung metastasis, and luciferin-stained tumor images^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS. Nr. 781661-94-7
Appearance Solid
Molecular Weight 443.29
Formel C₂₀H₁₉BrN₄O₃
Color Light yellow to green yellow
SMILES

O=C1C2=C(C(C3=CC=CC=C31)=O)[N+](CC4=NC=CN=C4)=C(C)N2CCOC.[Br-]
Synonyms

YM-155
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

4°C, sealed storage, away from moisture

* In solvent : -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture)

Publications (23)

All Cell Imaging/StainingIn Vivo Efficacy StudyIHCWB

Sort by:

Journal Impact Factor

Adv Sci (Weinh)

Chromosome Missegregation Triggers Tumor Cell Pyroptosis and Enhances Anti-Tumor Immunotherapy in Colorectal Cancer. [Abstract]

2025 Mar;12(12):e2409769. PMID: 39903759
Cell Death Dis

A small natural molecule CADPE kills residual colorectal cancer cells by inhibiting key transcription factors and translation initiation factors. [Abstract]

2020 Nov 15;11(11):982. PMID: 33191401
Cancer Lett

Survivin-targeted drug screening platform identifies a matrine derivative WM-127 as a potential therapeutics against hepatocellular carcinoma. [Abstract]

2018 Jul 1:425:54-64. PMID: 29608986

Sepantronium bromide purchased from MedChemExpress. Usage Cited in: Cancer Lett. 2018 Jul 1:425:54-64. [Abstract]

The cell model HepG2-Sur5P-EGFP-Sur3U was treated with Sepantronium bromide (YM155) at a final concentration of 100 nmol/ml. After 24 h later, the fluorescence strength of EGFP was recorded and the expression of Survivin was examined.

Sepantronium bromide purchased from MedChemExpress. Usage Cited in: Cancer Lett. 2018 Jul 1:425:54-64. [Abstract]

Huh-7 cell xenograft models were established by subcutaneously injection of 1 × 10⁶ cells per mouse in 4 groups of nude mice (n = 5/group). After five intratumoral injections of Sepantronium bromide (YM155) at 3 mg/ml, the tumor volume was counted weekly.

Sepantronium bromide purchased from MedChemExpress. Usage Cited in: Cancer Lett. 2018 Jul 1:425:54-64. [Abstract]

Huh-7 cell xenograft models were established by subcutaneously injection of 1 × 10⁶. cells per mouse in 4 groups of nude mice (n = 5/group). After five intratumoral injections of Sepantronium bromide (YM155) at 3 mg/ml. The xenografted tumors were weighed and compared.

Sepantronium bromide purchased from MedChemExpress. Usage Cited in: Cancer Lett. 2018 Jul 1:425:54-64. [Abstract]

Sepantronium bromide (YM-155, 3mg/mL)The xenograft tumor sections were examined by immunohistochemistry and TUNEL labeling. The expression levels of Survivin and the percentages of apoptotic cells in xenografted tumors were quantified within 5 high-power fields under microscope and showed in histograms.
Stem Cell Res Ther

Pulp stem cells with hepatocyte growth factor overexpression exhibit dual effects in rheumatoid arthritis. [Abstract]

2020 Jun 10;11(1):229. PMID: 32522231
Drug Deliv Transl Res

Leveraging quantum chemical properties in transfer learning for predicting blood-brain barrier permeability of drugs. [Abstract]

2025 Oct 29. PMID: 41160380
Mol Cancer Ther

Navitoclax, a Bcl-2/xL Inhibitor, and YM155, a Survivin Inhibitor, in Combination with Carboplatin, Effectively Inhibit Ovarian Cancer Tumor Growth. [Abstract]

2025 Apr 28:OF1-OF13. PMID: 40293279
Biochem Pharmacol

ONC212 enhances YM155 cytotoxicity by triggering SLC35F2 expression and NOXA-dependent MCL1 degradation in acute myeloid leukemia cells. [Abstract]

2024 Jun:224:116242. PMID: 38679209
Nutrients

Glycycoumarin Sensitizes Liver Cancer Cells to ABT-737 by Targeting De Novo Lipogenesis and TOPK-Survivin Axis. [Abstract]

2018 Mar 15;10(3):353. PMID: 29543705

Sepantronium bromide purchased from MedChemExpress. Usage Cited in: Nutrients. 2018 Mar 15;10(3):353. [Abstract]

Influences of YM155, a chemical inhibitor of survivin on ABT-737-induced apoptosis are analyzed by western blot.
Int Immunopharmacol

A multi-omics R-loop-linked risk program highlights CKS2-positive proliferative tumor cells as drivers of glioma growth. [Abstract]

2026 Apr 15:175:116421. PMID: 41763168
Sci Rep

Extracorporeal shock waves protect cardiomyocytes from doxorubicin-induced cardiomyopathy by upregulating survivin via the integrin-ILK-Akt-Sp1/p53 axis. [Abstract]

2019 Aug 21;9(1):12149. PMID: 31434946
Cancers (Basel)

Molecular Insights into the Anticancer Activity of Withaferin-A: The Inhibition of Survivin Signaling. [Abstract]

2024 Sep 5;16(17):3090. PMID: 39272948
Cancers (Basel)

Spironolactone, a Classic Potassium-Sparing Diuretic, Reduces Survivin Expression and Chemosensitizes Cancer Cells to Non-DNA-Damaging Anticancer Drugs. [Abstract]

2019 Oct 14;11(10):1550. PMID: 31614999
Cancers (Basel)

Brexpiprazole, a Serotonin-Dopamine Activity Modulator, Can Sensitize Glioma Stem Cells to Osimertinib, a Third-Generation EGFR-TKI, via Survivin Reduction. [Abstract]

2019 Jul 5;11(7):947. PMID: 31284441
BMC Complement Med Ther

Myricanol 5-fluorobenzyloxy ether regulation of survivin pathway inhibits human lung adenocarcinoma A549 cells growth in vitro. [Abstract]

2020 Sep 3;20(1):269. PMID: 32883260
Cancer Res Commun

Histone Deacetylase Inhibitors Target DNA Replication Regulators and Replication Stress in Ewing Sarcoma Cells. [Abstract]

2025 Jun 1;5(6):1034-1048. PMID: 40478628
Toxicol Appl Pharmacol

Arsenic trioxide-induced p38 MAPK and Akt mediated MCL1 downregulation causes apoptosis of BCR-ABL1-positive leukemia cells. [Abstract]

2020 Jun 15:397:115013. PMID: 32305283
Anticancer Res

Brexpiprazole Reduces Survivin and Reverses EGFR Tyrosine Kinase Inhibitor Resistance in Lung and Pancreatic Cancer. [Abstract]

2019 Sep;39(9):4817-4828. PMID: 31519584
Anticancer Res

AS602801 Sensitizes Ovarian Cancer Stem Cells to Paclitaxel by Down-regulating MDR1. [Abstract]

2019 Feb;39(2):609-617. PMID: 30711936

Sepantronium bromide purchased from MedChemExpress. Usage Cited in: Anticancer Res. 2019 Feb;39(2):609-617. [Abstract]

A2780 CSLCs are treated in the presence or absence of AS602801 (7.5 μM) and/or YM155 (10 nM) for 3 days, and then subjected to western blot analysis of survivin and glyceraldehyde 3-phosphate dehydrogenase (GAPDH).
Anticancer Res

AS602801, an Anticancer Stem Cell Candidate Drug, Reduces Survivin Expression and Sensitizes A2780 Ovarian Cancer Stem Cells to Carboplatin and Paclitaxel. [Abstract]

2018 Dec;38(12):6699-6706. PMID: 30504379
bioRxiv

2026 May 1.
bioRxiv

Low-Cost Robotic Manipulation of Live Microtissues for Cancer Drug Testing. [Abstract]

2024 Aug 6:2024.03.21.586169. PMID: 38586030
Res Sq

Targeting mTOR and Survivin Concurrently Potentiates Radiation Therapy in Renal Cell Carcinoma by Suppressing DNA Damage Repair and Amplifying Mitotic Catastrophe. [Abstract]

2023 Dec 23:rs.3.rs-3770403. PMID: 38196607
Research Square Preprint

2021 Jul.

Lösungsmittel & Löslichkeit

In Vitro:

H₂O : 50 mg/mL (112.79 mM; Need ultrasonic)

DMSO : 11.67 mg/mL (26.33 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.2559 mL

11.2793 mL

22.5586 mL

5 mM

0.4512 mL

2.2559 mL

4.5117 mL

10 mM

0.2256 mL

1.1279 mL

2.2559 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture). When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2 mg/mL (4.51 mM); Clear solution

This protocol yields a clear solution of ≥ 2 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: 2 mg/mL (4.51 mM); Clear solution; Need ultrasonic

This protocol yields a clear solution of 2 mg/mL. If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.0 mg/mL) to 900 μL Corn oil, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: PBS

Solubility: 50 mg/mL (112.79 mM); Clear solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Working solution concentration: 0.22 mg/mL

This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact

MedChemExpress (MCE) .

Protokoll

Cell Assay^[1]

The antiproliferative activity of Sepantronium bromide is measured. After treatment with Sepantronium bromide for 48 h, the cell count is determined by sulforhodamine B assay. The GI₅₀ value is calculated by logistic analysis, which is the drug concentration resulting in a 50% reduction in the net protein increase (as measured by sulforhodamine B staining) in control cells during the drug incubation. The assay is done in triplicate, and the mean GI₅₀ value is obtained from the results of four independent assays.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration^[1]

Five-week-old male nude mice (BALB/c nu/nu) are used for the assay. PC-3 cells (2×10⁶-3×10⁶) are injected into the flanks of the mice and allowed to reach a tumor volume of > 100 mm³ in tumor volume (length×width²×0.5). Sepantronium bromide is s.c. administered as a 3-day continuous infusion per week for 2 weeks using an implanted micro-osmotic pump or i.v. administered five times a week for 2 weeks. The percentage of tumor growth inhibition 14 days after initial Sepantronium bromide administration is calculated for each group using the following formula: MTV=100×{1-[(MTV of the treated group on day 14)-(MTV of the treated group on day 0)]/[(MTV of the control group on day 14)-(MTV of the control group on day 0)]}, where MTV is mean tumor volume. For both the frozen tumors and plasma samples, survivin expression levels are analyzed by Western blotting and Sepantronium bromide concentration by high-performance liquid chromatography/triple quadrupole mass spectrometry (LC/MS/MS) using validated methods.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (286 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Nakahara T, et al. YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts. Cancer Res. 2007 Sep 1;67(17):8014-21. [Content Brief]

[2]. Iisa T, et al. Radiosensitizing effect of YM155, a novel small-molecule survivin suppressant, in non-small cell lung cancer cell lines. Clin Cancer Res. 2008 Oct 15;14(20):6496-504. [Content Brief]

[3]. Guo K, et al. A combination of YM-155, a small molecule survivin inhibitor, and IL-2 potently suppresses renal cell carcinoma in murine model. Oncotarget. 2015 Aug 28;6(25):21137-47. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO / H₂O	1 mM	2.2559 mL	11.2793 mL	22.5586 mL	56.3965 mL
	5 mM	0.4512 mL	2.2559 mL	4.5117 mL	11.2793 mL
	10 mM	0.2256 mL	1.1279 mL	2.2559 mL	5.6396 mL
	15 mM	0.1504 mL	0.7520 mL	1.5039 mL	3.7598 mL
	20 mM	0.1128 mL	0.5640 mL	1.1279 mL	2.8198 mL
	25 mM	0.0902 mL	0.4512 mL	0.9023 mL	2.2559 mL
H₂O	30 mM	0.0752 mL	0.3760 mL	0.7520 mL	1.8799 mL
	40 mM	0.0564 mL	0.2820 mL	0.5640 mL	1.4099 mL
	50 mM	0.0451 mL	0.2256 mL	0.4512 mL	1.1279 mL
	60 mM	0.0376 mL	0.1880 mL	0.3760 mL	0.9399 mL
	80 mM	0.0282 mL	0.1410 mL	0.2820 mL	0.7050 mL
	100 mM	0.0226 mL	0.1128 mL	0.2256 mL	0.5640 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Keywords

Sepantronium bromide

23 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Sepantronium bromide

Anti-Infection Compound Library

Apoptosis Compound Library

Anti-Cancer Compound Library

Autophagy Compound Library

Anti-Lung Cancer Compound Library

Targeted Diversity Library

Anti-Prostate Cancer Compound Library

Cell Death Library

Bioactive Compound Library Max

Bioactive Compound Library

High-Throughput Bioactive Compound Library

RNA Binding Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) Sepantronium bromide

Biologische Aktivität

Chemical Information

Publications (23)

Lösungsmittel & Löslichkeit

Protokoll

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Sepantronium bromide

Anti-Infection Compound Library

Apoptosis Compound Library

Anti-Cancer Compound Library

Autophagy Compound Library

Anti-Lung Cancer Compound Library

Targeted Diversity Library

Anti-Prostate Cancer Compound Library

Cell Death Library

Bioactive Compound Library Max

Bioactive Compound Library

High-Throughput Bioactive Compound Library

RNA Binding Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) Sepantronium bromide

Biologische Aktivität

Chemical Information

Publications (23)

Lösungsmittel & Löslichkeit

Protokoll

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Sepantronium bromide Related Classifications

HY-10194 Related Classifications